These findings suggest that the observed anti-leukemic activity in TP53 mutated MDS/AML and particularly erythroid leukemias is likely associated with higher expression of the target and not cell-intrinsic sensitivity to the ADC. The gene discussed is TP53; the disease is myelodysplastic syndrome.